Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Morgan Creek Energy Stock Forward Split 2:1 Effective at Trade Date August 3, 2009
DALLAS, Aug. 4 /PRNewswire-FirstCall/ -- The Board of Directors of Morgan Creek Energy Corp. (the "Company") (OTC Bulletin Board: MCKE - News; M6C1-Frankfrurt) has authorized and approved a forward split of the Company's common shares with a payable date of August 3, 2009. The forward stock split provides for the issuance of new shares at a ratio of two shares to one share for every share of the Company's stock issued and outstanding. Shareholders of the Company will automatically receive two common shares for every common share held of record as of July 14, 2009 (the "Record Date"), and do not require any action on their part to receive the new shares.
Prior to the forward stock split, the Company had 17,016,196 shares of common stock issued and outstanding. Subsequent to the forward split, the Company will have 34,032,392 shares of common stock issued and outstanding. Commensurate with the forward stock split, the Company also increased its authorized capital structure to 66,666,666 shares of common stock, par value, $0.001.
About Morgan Creek Energy Corp.:
Morgan Creek Energy Corp. is a natural resource exploration company engaged in the acquisition and development of strategic oil and natural gas properties. For further information see: www.morgancreekenergy.com
Symbol: OTCBB - MCKE; Frankfurt/Berlin Symbol - M6C1, WKN No.: A0QYTM; ISIN: 61732R 206
SAFE HARBOR STATEMENT
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE.
EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH PROPERTY DEVELOPMENT AND FUNDING AS WELL AS THE RISKS SHOWN IN THE COMPANY'S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS EXPLORATION AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S PERIODIC REPORTS FILED FROM TIME-TO-TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.
THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKES FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
Stock Profiler.US: Stock Profiler.US: Stock Watch: ZAGG, GVSS, MCKE
07/10/2009 09:06:59 ET
New York, NY, Jul 10, 2009 (M2 PRESSWIRE via COMTEX News Network) -- ZAGG Inc. (OTCBB: ZAGG); GVI Security Solutions, Inc. (OTC Bulletin Board: GVSS); Morgan Creek Energy Corp. (OTC Bulletin Board: MCKE) (M6C1-Frankfrurt)
StockProfiler.US is Introducing Leading Microcap Companies! We welcome Investors to sign up and subscribe to our FREE Newsletter at www.stockprofiler.us. Please follow our thread on www.twitter.com at StockProfilerUS
-------------------------------------------
ZAGG Inc. closed at $6.00 Thursday, trading 66,477 shares.
Company News- July 9, 2009: ZAGG Opens New Office for AppSpace.com and Mobile App Development
ZAGG Inc. (OTCBB: ZAGG), a leader in mobile electronics and accessories including the award-winning invisibleSHIELD and ZAGGaudio brands, yesterday announced the opening of a new facility dedicated to the mobile application market.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About ZAGG Inc.
ZAGG Inc. designs, manufactures, and distributes protective clear coverings and accessories for consumer electronic and hand-held devices, worldwide under the brand names invisibleSHIELD and ZAGGaudio. ZAGG has also announced it will introduce AppSpace.com in summer 2009, an online destination for the fast-growing mobile app market, combined with the networking power of social media. The invisibleSHIELD is a protective, high-tech patented film covering, designed for iPods, laptops, cell phones, digital cameras, PDAs, watch faces, GPS systems, gaming devices, and other items. The patent-pending invisibleSHIELD application of clear protective film covering a device is the first scratch protection solution of its kind on the market, and has sold millions of units. Currently, ZAGG offers over 3,000 precision pre-cut designs with a lifetime replacement warranty through online channels, big box retailers like Best Buy, resellers, college bookstores, Mac stores and mall kiosks. The company continues to increase its product lines to offer additional electronic accessories and services to its tech-savvy customer base. For more product or investor information please visit the company's web site at www.ZAGG.com.
-------------------------------------------
GVI Security Solutions, Inc. closed at $0.321 Thursday, trading 10,200 shares.
Company News- July 9, 2009: GVI Security Solutions Samsung Cameras Selected by Major Air Freight Operator
GVI Security Solutions, Inc. (OTC Bulletin Board: GVSS), a leading provider of video security surveillance solutions featuring the complete Samsung Electronics line of products, announced yesterday that their Samsung Electronics cameras have been selected for an extensive, ongoing video surveillance upgrade and expansion project by a major United States based air freight operator.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About GVI Security Solutions, Inc.
GVI Security Solutions, Inc. (OTC Bulletin Board: GVSS) is a leading provider of video surveillance and security solutions, with sales and service representation throughout North, Central and South America. The company provides Samsung Electronics and GVI branded products, software and services to the homeland security and commercial markets. Their customers include governments, major retail chains, leading financial institutions and public and private school systems.
-------------------------------------------
Morgan Creek Energy Corp. closed at $0.3799 Thursday, trading 1,200 shares.
Company News- July 9, 2009: Morgan Creek Energy Enters Joint Drilling Agreement on Frio Draw Prospect in Curry County, New Mexico
Morgan Creek Energy Corp. (the "Company") (OTC Bulletin Board: MCKE) (M6C1-Frankfrurt) announced yesterday it has entered into an Letter Agreement dated July 9, 2009, with FormCap Corp. ("FormCap"), for joint drilling on the Company's Frio Draw gas prospect in Curry County, New Mexico.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About Morgan Creek Energy Corp.
Morgan Creek Energy Corp. is a natural resource exploration company engaged in the acquisition and development of strategic oil and natural gas properties. For further information, see www.morgancreekenergy.com.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stock Profiler.US, LLC's News Division includes but is not limited to: www.stockprofiler.us; www.associatesfortune.com; www.fastmoneytalk.com; www.markettelegraph.com; www.thewallstreetleader.com; and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.
Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL
CONTACT: StockProfiler.US e-mail: info@stockprofiler.us WWW: http://www.stockprofiler.us
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2009 M2 COMMUNICATIONS
Stockguru.com: Morgan Creek Energy Corp. is in the StockGuru Spotlight for July 10, 2009
07/10/2009 04:25:05 ET
Jul 10, 2009 (M2 PRESSWIRE via COMTEX News Network) -- DALLAS, TEXAS : StockGuru announces that Morgan Creek Energy Corp. (OTCBB: MCKE) is in the StockGuru Spotlight. Morgan Creek Energy Corp. is a natural resource exploration company engaged in the acquisition and development of strategic oil and natural gas properties.
On Thursday, the company put out news regarding the entering into a Letter Agreement dated July 9, 2009, with FormCap Corp. ('FormCap'), for joint drilling on the Company's Frio Draw gas prospect in Curry County, New Mexico. FormCap is required to drill and complete two mutually defined targets on the Company's leases in return for an earned 50% Working Interest (40.75% Net Revenue Interest) in the entire Frio Draw Prospect. Following the initial well drilling and completion, Morgan Creek Energy's management and land team will work with FormCap to establish additional targets on the Frio Draw based on technical data and drill results. The two companies will jointly fund additional targets and have committed to a minimum five-hole drill program in order to effectively test the Frio Draw.
Shares for Morgan Creek Energy Corp. (OTCBB: MCKE) were steady during the morning of trading on Thursday and closed slightly up at closing.
To view our StockGuru Spotlight on Morgan Creek Energy Corp. (OTCBB: MCKE), please visit: http://www.stockguru.com
What is the StockGuru Spotlight?
The StockGuru Spotlight features stocks that we expect some action in. Generally speaking we expect a strong showing in the market based on the market, our knowledge of the stock and the buzz in the markets. Many times these will be stocks that have big news out recently, there is fresh interest in getting the word out on these stocks or we hear a buzz in our day to day contacts on these stocks. If we think it is going to move or see action, we put it in the StockGuru Spotlight. If we are compensated for a stock in the Spotlight, it will be clearly disclosed within this Spotlight Announcement.
If you think a company should be featued in the StockGuru Spotlight, please let us know. If you are a key person for a publicly traded company, we can consider your company for either a StockGuru Spotlight or a StockGuru Profile. Please contact our Publisher John Pentony at the john@stockguru.com. You may also telephone John Pentony at (469) 252-3031.
Stockguru.com ("SG") provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.Stockguru.com or mentioned herein.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
CONTACT: John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: john@stockguru.com WWW: http://www.stockguru.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2009 M2 COMMUNICATIONS
DALLAS, July 9 /PRNewswire-FirstCall/ -- Morgan Creek Energy Corp. (the "Company") (OTC Bulletin Board: MCKE - News; M6C1-Frankfrurt) has entered into an Letter Agreement dated July 9, 2009, with FormCap Corp. ("FormCap"), for joint drilling on the Company's Frio Draw gas prospect in Curry County, New Mexico. FormCap is required to drill and complete two mutually defined targets on the Company's leases in return for an earned 50% Working Interest (40.75% Net Revenue Interest) in the entire Frio Draw Prospect
Following the initial well drilling and completion, Morgan Creek Energy's management and land team will work with FormCap to establish additional targets on the Frio Draw based on technical data and drill results. The two companies will jointly fund additional targets and have committed to a minimum five-hole drill program in order to effectively test the Frio Draw.
About Morgan Creek Energy Corp.:
Morgan Creek Energy Corp. is a natural resource exploration company engaged in the acquisition and development of strategic oil and natural gas properties. For further information see: www.morgancreekenergy.com
Symbol: OTCBB - MCKE; Frankfurt/Berlin Symbol - M6C1, WKN No.: A0QYTM; ISIN: 61732R 206
Contact North America: Investor Relations
Tel.: 214-722-6490
Contact Europe: Investor Relations
Tel.: 49-69-7593-8467
SAFE HARBOR STATEMENT
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE.
EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH PROPERTY DEVELOPMENT AND FUNDING AS WELL AS THE RISKS SHOWN IN THE COMPANY'S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS EXPLORATION AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S PERIODIC REPORTS FILED FROM TIME-TO-TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.
THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKES FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
check out the depth/LII chart....
http://www.otcbb.com/asp/info_center.asp?symbol=MCKE
contact info....
Corporate Offices: Morgan Creek Energy Corp.
Quorum 5050 Quorum Drive, Suite 700 Dallas, Texas 75254
Contact N. America: Tel.: 866-590-6589
Contact Europe: Tel.: 49-69-7593-8467 Tel.:
Direct: 214-321-0603
Fax: (866) 559-7565
email: info@morgancreekenergy.com
website....
http://www.morgancreekenergy.com
check this out....
http://biz.yahoo.com/e/081105/mcke.ob8-k.html
Thanks for the link
I am a US, and my broker is Sharebuilder
Hey Norman i got a packet from my broker about all of the "rights" that the company sent to them just wondering if you got anything
gg
This article is from Bellwether Report.
On Thursday we had a conversation with Brian Sozzi of Wall Street Strategies to ask his professional opinion on Morgan Creek Energy Corp. (OTCBB:MCKE).
Sector : Basic Materials
Industry : Oil & Gas Equipment & Services
Year End : December 31st 2008
Head Quarter : Dallas, Texas
Websites : http://www.morgancreekenergy.com
Brief Description:
Morgan Creek Energy Corp. engages in the location, exploration, acquisition, and development of oil and gas properties in the United States. It has a 100% working interest in approximately 2,035 gross acres of the Quachita prospect leases located in within the Ouachita Trend in the Texas. The company also holds a 75% the Chapman lease covering approximately 240 acres in Okfuskee County and the Hurley Lease covering approximately 320 acres in Okfuskee County in Oklahoma. In addition, it owns a 100% working interest in the Browder Barnett shale oil and gas prospect in Cooke County, and in the Mata lease located in Webb County, and the Peters Ranch lease located in Duval County in Texas. The company was founded in 2004.
KEY EXECUTIVES
Mr. D. Bruce Horton , 63
Chief Financial Officer, Principal Accounting Officer, Sec., Treasurer, Stock Option Plan Administrator, Director and Member of Audit Committee
Mr. Thomas Alden Markham II, P. Geo, 57
Chief Geologist
Mr. David Urquhart B.Sc. B.Eng. P.Eng.,
Chief Exec. Officer, Pres
Mr. William P. Begley ,
Mang. of Operations
This conversation was conducted on June 12th 2008.
Q: What’s your take on Morgan Creek Energy Corp.?
A: This is certainly an intriguing company to take a look at. The company has not generated any revenues as of yet, rather focusing on land lease acquisitions to further explore for natural gas.
Q: What more can you tell us about the company?
A: Its main project in Texas unearthed significant natural gas reserves in four out of five leased land zones. The findings have led management to secure all immediate rights relating to oil and gas in the area providing control over any potential major structural play that develops as a result of its in-depth exploration.
Q: Analytically speaking, what would you tell investors looking to position themselves in this stock?
A: Of course there are risks for any company that is not generating revenues, but at this point there is enough potential to warrant rating the stock a speculative buy.
thanks for your help norman
we have been having some good days, i hope this is another one
So since im a US investor will this have nothing to do with me, is that the way you understand it?
I hope there are good things to come from this
NEWS RELEASE
Morgan Creek Energy Hires OPS Group Ltd. as Contract Operator To Drill
Oil / Gas Test Program on Frio Draw Prospect, New Mexico
Dallas, Texas / PR Newswire – June 12, 2008 –Morgan Creek Energy Corp., (the
“Company”) (SYMBOL MCKE-OTCBB, M6C1-Frankfrurt) has signed an Operating
Contract with OPS Group Limited of Houston, Texas to act as its Operator in the Frio
Draw field leases acquired by Morgan Creek in Curry County, New Mexico over the last
two months. Morgan Creek holds a 100% working interest in approximately 14
contiguous sections in T2&3N, R34E.
The Company has initiated plans through OPS to drill a vertical test into the San
Andres carbonate section, and to acquire the necessary tubulars required to drill and
complete the proposed test. The Company expects to be ready to stake and construct
the project’s initial drill site within the next two weeks, so that the test can be spudded
during the next available drilling window.
The San Andres, a carbonate sequence in the Frio Draw area, is of Permian Age and
has been one of the most prolific oil producing horizons in North America. There are
three major porosity cycles developed within the San Andres series. Each cycle
represents a separate transgressive event, and each event is characterized by a lower
shale sequence overlain by carbonates that grade into evaporates, typically oil. These
cycles represent the three primary targets for oil and gas bearing horizons.
Morgan Creek’s Frio Draw area focuses on the middle of the three targets. Detailed log
analyses on over 100 wells penetrating this cycle have delineated areas where there is a
noted increase in porosity and permeability. Within this trend, the majority of analyzed
wells demonstrated oil and gas shows. No commercial production has ever been
attempted.
Morgan Creek’s depositional - diagenetic modeling, based on Shell Oil’s stratigraphic
testing of this porosity cycle in the mid 1960’s, has defined several prospective
productive areas.
About OPS Group Limited
OPS Group Limited, formed in 2005, provides a cost-effective means of outsourcing
engineering, regulatory and accounting services as an operating package. The company
provides its contract clients with knowledgeable and skilled professionals to perform the
critical task of well operations on a short or long term basis. OPS provides these
services through a contractual arrangement with New Tech Engineering, LP, founded in
1998. New Tech is one of the largest domestic engineering-consulting firms in the
energy industry with regional offices in ten cities and with more than 400 well site,
engineering, and project management consultants working domestically and around the
world.
About Morgan Creek Energy Corp.:
Morgan Creek Energy Corp. is a natural resource exploration company engaged in the
acquisition and development of strategic oil and natural gas properties. For further
information see: www.morgancreekenergy.com
Symbol: OTCBB – MCKE; Frankfurt/Berlin Symbol – M6C1, WKN No.: A0QYTM; ISIN:
61732R 206
Contact North America: Investor Relations
Tel.: 866-590-6589
Contact Europe: Investor Relations
Tel.: 49-69-7593-8467
SAFE HARBOR STATEMENT
THIS NEWS RELEASE CONTAINS “FORWARD-LOOKING STATEMENTS”, AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES
SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY
STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE.
EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING
STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM
ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT
HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS “ESTIMATE,”
“ANTICIPATE,” “BELIEVE,” “PLAN” OR “EXPECT” OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES
FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH PROPERTY DEVELOPMENT AND FUNDING AS WELL AS
THE RISKS SHOWN IN THE COMPANY’S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN
OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY
APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY’S ABILITY AND LEVEL OF SUPPORT FOR
ITS EXPLORATION AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY’S DEVELOPMENT EFFORTS WILL
SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF
THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO
UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH
THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE,
THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD
CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY’S
PERIODIC REPORTS FILED FROM TIME-TO-TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.
THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKES FULL RESPONSIBILITY FOR ITS CONTENTS. EACH
OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE. THIS NEWS
RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE
SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR
QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
Hey Norm
I was wondering if u know anything about the latest PR, heres a link if u havent read it. I was just wondring if you might now what it means
http://biz.yahoo.com/cnw/080613/lorus_rights_offering.html?.v=1
Thanks
GG
looks like some good things are happening here
you better buy now!!!
something good is going on
im hoping for some good news to come soon!!!
LORUS INITIATES DEVELOPMENT PROGRAM EXPLORING NOVEL ROUTE OF ADMINISTRATION FOR LOR-2040
TORONTO, CANADA, APRIL 22, 2008 – Lorus Therapeutics Inc. (‘Lorus’), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the start of a development program aimed at expanding the therapeutic application of its lead clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer.
The new development program will examine direct (intravesical) administration of LOR-2040 into the bladder as a treatment for superficial or non-invasive bladder cancer. Formal toxicology evaluation, which is currently in progress, will be used to determine the appropriate human dose and dose schedule for LOR-2040 with this route of administration.
Results of these studies will be used in support of an Investigational New Drug (IND) application for the use of LOR-2040 in the treatment of bladder cancer. Lorus intends to submit the IND during Q3, 2008, following successful completion of the toxicology program.
LOR-2040, formerly known as GTI-2040, has shown potent antiproliferative activity and target downregulation in bladder cancer in preclinical studies. LOR-2040 is currently being investigated in several phase I and phase II clinical trials in a broad range of cancer indications, both alone and in combination with a number of standard cancer therapies. In clinical trials, LOR-2040 has demonstrated a high safety profile when administered intravenously, which is the current route of administration for this drug.
In the U.S. more than 60,000 new cases of bladder cancer are diagnosed each year, which accounts for approximately 13,000 deaths annually. At initial diagnosis, up to 90% of subjects with bladder cancers have superficial disease that is confined to the inner layers of tissue in the urinary bladder. Systemic chemotherapy is considered less effective than the intravesical (instilled in the bladder) agents in treating locally confined, superficial bladder tumors. In fact intravesical administration exposes the bladder tumor to higher levels of drugs that may prevent tumor cells from becoming invasive and spreading (metastasizing) to other organs. This treatment method is a standard regimen used for many approved chemotherapy drugs to treat superficial bladder cancer.
“I am pleased that we have initiated the studies that explore a novel way of administering LOR-2040 directly to bladder tumors and that we are on schedule to advance LOR-2040 in this indication”, said Dr. Aiping Young, President and CEO of Lorus. “Bladder cancer is seventh most common cancer worldwide and is a significant target indication for new therapeutics. Coupled with the high risk of recurrence, even in patients with early stage disease, adding a non-systemic treatment to the currently available treatment options has significant potential.” 1
About LOR-2040
LOR-2040 (formerly GTI-2040) is an RNA-targeted drug candidate specific for the R2 subunit of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. LOR-2040 has demonstrated strong antitumor and antimetastatic activity in a variety of tumor types in both in vivo and in vitro models. LOR-2040 is under study in a multiple Phase I/II clinical program, including an advanced Phase II clinical trial with LOR-2040 and high dose Ara-C (HiDAC) in refractory and relapsed Acute Myeloid Leukemia (AML). The R2 target has been described as a malignant determinant that is elevated in a wide range of tumors, which can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential.
About Lorus
Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics for the treatment of cancer that are at various stages of development spanning discovery to clinical trials. Lorus’ goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drugs that can be used, either alone, or in combination with other agents, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: financings and corporate reorganizations, the establishment of corporate alliances, the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance, achievements or the transactions described in this press release to be materially different from any future results, performance, achievements or transactions described in this press release, if at all, that may be expressed or implied by such forward-looking statements, including, among others: the progress of negotiations; our ability to obtain regulatory, security holder and other approvals; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission
2
underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Lorus Therapeutics’ recent press releases are available through its website at www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to www.Sedar.com. For SEDAR filings prior to July 10, 2007 you will find these under the company profile for Global Summit Real Estate Inc. (Old Lorus).
Enquiries:
For further information, please contact:
Lorus Therapeutics Inc.
Dr. Saeid Babaei, 1-416-798-1200 ext. 490
ir@lorusthera.com
3
REALLY GOOD NEWS!!!!!!
LORUS THERAPEUTICS ANNOUNCES EXCLUSIVE MULTINATIONAL LICENSE AGREEMENT WITH ZOTICON BIOVENTURES FOR VIRULIZIN®
- Agreement includes upfront, milestone and royalty payments on future sales -
TORONTO, CANADA – (April 8, 2008) – Lorus Therapeutics Inc. (“Lorus”) (TSX: LOR; AMEX: LRP), a biopharmaceutical company dedicated to the research and development of pharmaceutical products and technologies for the management of cancer, announced today that its subsidiary GeneSense Technologies, Inc. (“GeneSense”) has signed an exclusive multinational license agreement with Zor Pharmaceuticals LLC formed as a subsidiary of Zoticon Bioventures Inc. (“Zoticon”), a research-driven biopharmaceutical group, to further develop and commercialize Virulizin® for human therapeutic applications. The initial clinical development of Virulizin® under the agreement will be in advanced pancreatic cancer.
Under the terms of the agreement, GeneSense will be entitled to receive payments in excess of US$10 million upon achievement of various milestone events and royalties that vary from 10-20% depending on achieving of sales of Virulizin® and subject to certain other adjustments. In addition, a wholly owned subsidiary of Lorus, Pharma Immune Inc. (“Pharma Immune”) will receive 25% of the initial equity in Zor Pharmaceuticals. Pharma Immune’s equity will not be subject to dilution on the first US$5 million of financing in Zor Pharmaceuticals. Thereafter, Pharma Immune has, at its option, a right to participate in any additional financings to maintain its ownership level. In addition, GeneSense has entered into a Service Agreement with Zor Pharmaceuticals to assist in the transfer of knowledge and establish a strong foundation for moving forward with the development program for Virulizin.
Zor Pharmaceuticals will be responsible for the cost of all the clinical development, regulatory submissions and commercialization of Virulizin® in North and South America and Europe. GeneSense will retain rights in all other countries, including Japan, Australia and New Zealand.
"We are delighted to enter into this transaction with Zoticon, which shares our vision in the potential of Virulizin® and has the expertise and financial commitment to bring Virulizin® to market", stated Dr. Aiping Young, President and Chief Executive Officer of Lorus. “We believe that this drug has significant potential as a treatment option not only for patients with advanced pancreatic cancer, one of the most difficult cancers to treat, but also, upon further development, for other cancer indications. This arrangement provides significant potential value to our shareholders, representing Lorus’ commitment in maximizing the commercial potential of its anticancer products."
“Zoticon is very excited to be involved with the Virulizin® program. We have already begun to lay the groundwork for Zor Pharmaceuticals to continue product development and ultimately commercialization of this novel drug,” stated Asher Nathan, Managing Director of Zoticon.
1
Lorus invites analysts and media to participate in a conference call on April 9, 2008 at 3:00 pm Eastern Time. Shareholders are invited to listen to the call by telephone and the call will be available on the website (http://www.lorusthera.com/) following completion. Dial in numbers are below:
Toronto: 1-416-644-3422
Toll-free: 1-800-732-0232
About Virulizin®
Virulizin® is a novel biological response modifier (or immunotherapeutic agent) that stimulates a patient’s immune system through several mechanisms, including the activation of macrophages and the infiltration of natural killer cells into tumors. Virulizin® has demonstrated high levels of antitumor activity against a number of cancer indications including pancreatic cancer. Virulizin® has been granted orphan drug status and fast track status from the United States FDA and orphan designation from the Marketing Authorization Application with the European Medical Evaluation Agency (EMEA). A drug that receives fast track designation must demonstrate that it is intended for the treatment of a serious or life-threatening condition and that it has the potential to address unmet medical needs for the condition.
Virulizin® is a registered trademark owned by Lorus Therapeutics Inc.
About Lorus
Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus’ goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.
About Zoticon
Zoticon is a privately held global drug development and healthcare investment firm with a portfolio of life-sciences-focused companies. Zoticon’s business model is to in-license novel therapeutics, and the formation of new biotechnology companies.
For further information on Zoticon, please visit their website at www.zoticon.com.
Forward-Looking Statements for Lorus
This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: financings and corporate reorganizations, the establishment of corporate alliances, the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance, achievements or the transactions described in this press release to be materially different from any future results, performance,
2
achievements or transactions described in this press release, if at all, that may be expressed or implied by such forward-looking statements, including, among others: the progress of negotiations; the inherent risks in early stage drug development including demonstrating efficacy; the achievement of milestones, milestones and royalty payments, the successful development of Virulizin; development time/cost and the regulatory approval process; the progress of clinical trials; our ability to find and enter into agreements with potential partners; the dilution of Pharma Immune’s interest in Zor Pharmaceuticals; and changing market conditions.
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Lorus Therapeutics’ recent press releases are available through Lorus’ website at www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to Sedar.com. For SEDAR filings prior to July 10, 2007 you will find these under the company profile for Global Summit Real Estate Inc.
Enquiries:
For further information, please contact:
Lorus Therapeutics Inc.
Dr. Saeid Babaei, 1-416-798-1200 ext. 490 or 1-416-268-6181
ir@lorusthera.com
Zoticon Bioventures
Dr. Asher Nathan, 972 2 9995858
asher@zoticon.com
3
O and why did the price not triple, why is it still close to where it was before the reversal? I see bids in the .30s and I see ask in the $1 range? whats going on I wish the company would release info
I never got anything about voting for the reverse did anyone else?
Is there anyone still here that owns any shares?
Morgan Creek Energy Announces Reverse Stock Split and Issuance of New Trading Symbol and CUSIP Number
Tuesday April 22, 9:15 am ET
DALLAS, April 22 /PRNewswire-FirstCall/ -- In accordance with documentation filed with the NASDAQ Stock Market, Morgan Creek Energy Corp., a Nevada corporation (the "Company") effectuated a reverse stock split (the "Reverse Stock Split") of its shares of common stock as of open of market Tuesday, April 22, 2008. The ratio of the distribution for the Reverse Stock Split is one share for three shares (1:3) issued and outstanding.
ADVERTISEMENT
Each shareholder of the Company holding three shares of common stock will hold in lieu thereof hold of record one share of common stock on the Company. This will be reflected on the records of the Company without any action on the part of the shareholders of the Company.
The total number of shares of common stock issued and outstanding pre- Reverse Stock Split is 41,976,589. The total number of shares of common stock issued and outstanding post-Reverse Stock Split will be 13,992,196.
In accordance with the Reverse Stock Split, the Company's trading symbol and CUSIP number have changed to:
Trading Symbol: MCKE
CUSIP No.: 61732R 206
About Morgan Creek Energy Corp.: Morgan Creek Energy Corp. is a natural resource exploration company engaged in the acquisition and development of strategic oil and natural gas properties. For further information see: http://www.morgancreekenergy.com
whats going on with this company, I havent heard anything in a while. Whats the news on the well near Waco, Tx